clinical trial · NCT07483346
IASO-782 in Systemic Lupus Erythematosus
Shanghai IASO Biotechnology Co., Ltd·phase1·not yet recruiting·n = 20
SLE - Systemic Lupus ErythematosusIASO-782 injectionPlacebo
brief summary
his study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with SLE. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of SLE.
started
Apr 30, 2026
primary completion
Aug 31, 2027
completion
May 31, 2028
last updated
Mar 19, 2026
detailed description
This study is a multiple-dose escalation study in subjects with SLE. The study is designed to enroll subjects with SLE. This study will evaluate the safety and preliminary dose range of IASO-782 in subjects with SLE at the following dose levels:4mg/kg，6mg/kg and 10mg/kg.
official title
A Phase Ib Study to the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of IASO-782 in Patient With Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol